In addition to MMR status, the analysis of KRAS, NRAS, and BRAF mutation status has become standard of care in CRC patient biopsies and determines whether patients will receive treatment with EGFR inhibitors [5, 6]. The gene discussed is BRAF; the disease is colorectal carcinoma.